Tonix Pharmaceuticals Holding Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Tonix Pharmaceuticals Holding Corp. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue10.097.770.000.000.000.000.00
Cost of Revenue7.774.740.000.000.000.000.00
Gross Profit2.333.030.000.000.000.000.00
Operating Expenses
Research & Development39.9786.6681.8868.8436.1618.1917.56
Selling, General & Administrative40.1034.7530.2223.4714.3510.648.76
Operating Expenses77.48121.41112.0992.3150.5128.8326.32
Operating Income-75.15-118.38-112.09-92.31-50.51-28.83-26.32
Other Income/Expense
Interest Income0.000.001.870.030.050.000.23
Interest Expense0.000.000.000.000.000.000.00
Other Income/Expense-54.891.721.870.000.000.000.00
Income
Income Before Tax-130.04-116.66-110.22-92.29-50.46-28.62-26.09
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-130.04-116.66-110.22-92.29-50.46-28.62-26.09
Net Income - Continuous Operations-130.04-116.66-110.22-92.290.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-71.73-114.09-110.84-92.26-50.48-28.59-26.27
EBIT-75.15-118.38-112.09-92.31-50.51-28.62-26.32
Depreciation & Amortization3.424.291.250.050.030.000.00
Earnings Per Share
Basic EPS-177.00-14720.00-65400.00-119080.00-110.00-121.00-260.00
Diluted EPS-177.00-14720.00-65400.00-119080.00-110.00-121.00-260.00
Basic Shares Outstanding0.740.010.000.000.470.260.11
Diluted Shares Outstanding0.740.010.000.000.470.260.11